RU2001121019A - The use of maxonidine for the treatment of post-infarction conditions - Google Patents

The use of maxonidine for the treatment of post-infarction conditions

Info

Publication number
RU2001121019A
RU2001121019A RU2001121019/14A RU2001121019A RU2001121019A RU 2001121019 A RU2001121019 A RU 2001121019A RU 2001121019/14 A RU2001121019/14 A RU 2001121019/14A RU 2001121019 A RU2001121019 A RU 2001121019A RU 2001121019 A RU2001121019 A RU 2001121019A
Authority
RU
Russia
Prior art keywords
formula
physiologically acceptable
pharmaceutical compositions
acceptable acid
infarction
Prior art date
Application number
RU2001121019/14A
Other languages
Russian (ru)
Other versions
RU2261097C2 (en
Inventor
Регина Гертруда ШУМАКЕР
Original Assignee
Зольвай Фармасьютиклз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зольвай Фармасьютиклз Гмбх filed Critical Зольвай Фармасьютиклз Гмбх
Publication of RU2001121019A publication Critical patent/RU2001121019A/en
Application granted granted Critical
Publication of RU2261097C2 publication Critical patent/RU2261097C2/en

Links

Claims (4)

1. Применение 4-хлор-5-[(4,5-дигидро-1Н-имидазол-2-ил)амино]-6-метокси-2-метилпиримидина формулы I1. The use of 4-chloro-5 - [(4,5-dihydro-1H-imidazol-2-yl) amino] -6-methoxy-2-methylpyrimidine of the formula I
Figure 00000001
Figure 00000001
 и его физиологически приемлемых кислотно-аддитивных солей для получения фармацевтических композиций, предназначенных для лечения обусловленных инфарктом миокарда поражений сердечной мышцы.and its physiologically acceptable acid addition salts for the manufacture of pharmaceutical compositions for the treatment of heart muscle damage due to myocardial infarction. 2. Применение по п.1, отличающееся тем, что соединение формулы I по п.1 или его физиологически приемлемые кислотно-аддитивные соли используют для получения фармацевтических композиций, предназначенных для лечения обусловленных инфарктом миокарда поражений сердечной мышцы в острой стадии заболевания и/или в постинфарктном периоде.2. The use according to claim 1, characterized in that the compound of formula I according to claim 1 or its physiologically acceptable acid addition salts is used to obtain pharmaceutical compositions for the treatment of cardiac muscle damage due to myocardial infarction in the acute stage of the disease and / or post-infarction period. 3. Применение по п.2, отличающееся тем, что соединение формулы I по п.1 или его физиологически приемлемые кислотно-аддитивные соли используют для получения фармацевтических композиций, предназначенных для лечения обусловленных инфарктом миокарда поражений сердечной мышцы в хронической постинфарктной стадии.3. The use according to claim 2, characterized in that the compound of formula I according to claim 1 or its physiologically acceptable acid addition salts is used to obtain pharmaceutical compositions for treating cardiac muscle damage caused by myocardial infarction in the chronic post-infarction stage. 4. Способ получения фармацевтических композиций для лечения обусловленных инфарктом миокарда поражений сердечной мышцы, отличающийся тем, что из эффективного, способствующего процессу выздоровления и/или реабилитации функционального состояния сердечной мышцы количества соединения формулы I по п.1 или его физиологически приемлемых кислотно-аддитивных солей совместно с обычными фармацевтическими вспомогательными веществами изготавливают соответствующую лекарственную форму.4. A method of producing pharmaceutical compositions for treating cardiac muscle damage caused by myocardial infarction, characterized in that from the effective, conducive to the healing process and / or rehabilitation of the functional state of the heart muscle, the amount of the compounds of formula I according to claim 1 or its physiologically acceptable acid additive salts together with the usual pharmaceutical excipients, the corresponding dosage form is prepared.
RU2001121019/14A 1999-02-01 2000-01-28 Applying moxonidine for treatment of post-infarction states RU2261097C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19903780.9 1999-02-01
DE19903780 1999-02-01

Publications (2)

Publication Number Publication Date
RU2001121019A true RU2001121019A (en) 2003-06-10
RU2261097C2 RU2261097C2 (en) 2005-09-27

Family

ID=7895940

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001121019/14A RU2261097C2 (en) 1999-02-01 2000-01-28 Applying moxonidine for treatment of post-infarction states

Country Status (26)

Country Link
US (1) US7041303B2 (en)
EP (1) EP1150680B1 (en)
JP (1) JP4686027B2 (en)
KR (1) KR20010092793A (en)
CN (1) CN1166363C (en)
AT (1) ATE286731T1 (en)
AU (1) AU774855B2 (en)
BR (1) BR0007894A (en)
CA (1) CA2361600C (en)
CZ (1) CZ20012615A3 (en)
DE (2) DE50009220D1 (en)
DK (1) DK1150680T3 (en)
ES (1) ES2235829T3 (en)
HK (1) HK1042650B (en)
HU (1) HUP0105210A3 (en)
IL (1) IL144621A (en)
NO (1) NO321061B1 (en)
NZ (1) NZ513869A (en)
PL (1) PL195124B1 (en)
PT (1) PT1150680E (en)
RU (1) RU2261097C2 (en)
SK (1) SK10082001A3 (en)
TR (1) TR200102221T2 (en)
UA (1) UA67822C2 (en)
WO (1) WO2000045820A1 (en)
ZA (1) ZA200105827B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850331B (en) * 2012-09-17 2015-05-20 符爱清 4, 6-dichloro-2-methyl-5-(1-acetyl-2-imidazoline-2-yl)-aminopyrimidine preparation method
CN103483268B (en) * 2013-09-17 2015-10-14 常州大学 The preparation method of a kind of 4,6-bis-chloro-2-methyl-5-nitro pyrimidine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3739779A1 (en) * 1987-11-24 1989-06-08 Beiersdorf Ag PHARMACEUTICAL PRAEPARATE
TR199802496T2 (en) * 1996-06-06 1999-02-22 Eli Lilly And Company Formulation for the treatment of congestive heart failure.

Similar Documents

Publication Publication Date Title
RU98100107A (en) SUBSTITUTED LIPOSACHARIDES USED FOR THE TREATMENT AND PREVENTION OF ENDOTOXYCOSIS
EP2289521A3 (en) Compositions and methods for use in tergeting vascular destruction
RU97115713A (en) COMPOUNDS CONTAINING PETROPYRANES AND METHOD OF APPLICATION
RU2001128504A (en) Growth promoting compositions
RU2003134544A (en) AMRIDES OF ANTRANILIC ACID, METHODS FOR PRODUCING THEM, THEIR APPLICATION AS ANTIARRHYTHMIC MEDICINES, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
RU2003121236A (en) AILATED AMIDES OF FURAN- AND THIOPHENCARBOXYLIC ACIDS WITH LOCKING POTASSIUM CHANNEL ACTION
RU2007101653A (en) Derivatives of 1-azabicyclo [3.3.1] NONANOV
RU2006135653A (en) METHODS Preventing Fibrosis
RU99109969A (en) NEW DERIVATIVES OF PIPERIDIN-KETOKARBONIC ACID, THEIR RECEPTION AND APPLICATION
RU2004132856A (en) PHARMACEUTICAL PRODUCT WITH MODIFIED RELEASE
RU2007138582A (en) ORAL DOSAGE FORMS OF HEMCITABINE DERIVATIVES
JP2010505865A5 (en)
RU96106426A (en) BENZONITRILES AND BENZOFLUORIDES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PRODUCTION, METHOD FOR COMBATING DISEASES
RU2005121927A (en) DERIVATIVES OF AN Anhydrous Crystalline Azidocytosine Half Sulfate
RU96109699A (en) GUANIDIDES OF ALKENILKARBONIC ACIDS, METHOD OF THEIR RECEIVING, CONTAINING THEIR MEDICATION OR DIAGNOSTIC TOOL
RU96115459A (en) DERIVATIVES 4-SULFONIL-OR 4-SULPHINYL-BENZOILGUANIDINE
JPH11189534A (en) Intravenous administration form of thalidomide for treating immunological disease
RU2001121019A (en) The use of maxonidine for the treatment of post-infarction conditions
RU95109157A (en) ANTIHIPPERGLICEMICALLY EFFECTIVE PHARMACEUTICAL COMPOSITION
US4389415A (en) Method of treating hypertension
RU2004131214A (en) METHODS FOR TREATING COGNITIVE DISORDERS
HU202754B (en) Process for producing flavoxate derivatives and pharmaceutical compositions containing them as active components
RU2001118854A (en) OPTICALLY ACTIVE DERIVATIVE OF Pyridyl-4H-1,2,4-Oxadiazine AND ITS APPLICATION FOR TREATMENT OF VASCULAR DISEASES
CN1112920C (en) Aminotetralin derivative for the therapy of cardiovascular diseases
RU2009113616A (en) TARTRATE DERIVATIVES FOR APPLICATION AS INHIBITORS OF THE BLOOD FACTOR BLOOD IXA